Literature DB >> 35028714

Disease-specific complications and multidisciplinary interventions in achondroplasia.

Hiroshi Kitoh1,2, Masaki Matsushita3, Kenichi Mishima3, Yasunari Kamiya3, Kenta Sawamura3.   

Abstract

Achondroplasia (ACH) is the most common skeletal dysplasia and characterized by a disproportionate short stature, macrocephaly with frontal bossing, exaggerated lumbar lordosis, and trident hands. It is induced by activated mutations in the fibroblast growth factor receptor 3 (FGFR3) gene. In addition to short stature, patients with ACH have a high prevalence of medical complications, including upper airway obstructive apnea, increased mortality, foramen magnum stenosis, hydrocephalus, developmental delay, recurrent ear infections, genu varum, obesity, and spinal canal stenosis, throughout their whole life. Several investigational drugs that modulate abnormal FGFR3 signaling have recently emerged, vosoritide being the most developed. This review presents the different disease-specific complications of ACH occurring in neonates, infants, childhood, adolescent, and adults and reports the current multidisciplinary interventions for these various complications. Moreover, we propose treatment strategies for children with ACH from the perspective of quality of life in adulthood.
© 2021. The Japanese Society Bone and Mineral Research.

Entities:  

Keywords:  Achondroplasia; Complications; Current management; Quality of life; Therapeutic strategy

Mesh:

Year:  2022        PMID: 35028714     DOI: 10.1007/s00774-021-01298-z

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  47 in total

Review 1.  Achondroplasia.

Authors:  Geneviève Baujat; Laurence Legeai-Mallet; Georges Finidori; Valérie Cormier-Daire; Martine Le Merrer
Journal:  Best Pract Res Clin Rheumatol       Date:  2008-03       Impact factor: 4.098

2.  Epidemiology of achondroplasia: A population-based study in Europe.

Authors:  Alessio Coi; Michele Santoro; Ester Garne; Anna Pierini; Marie-Claude Addor; Jean-Luc Alessandri; Jorieke E H Bergman; Fabrizio Bianchi; Ljubica Boban; Paula Braz; Clara Cavero-Carbonell; Miriam Gatt; Martin Haeusler; Kari Klungsøyr; Jennifer J Kurinczuk; Monica Lanzoni; Nathalie Lelong; Karen Luyt; Olatz Mokoroa; Carmel Mullaney; Vera Nelen; Amanda J Neville; Mary T O'Mahony; Isabelle Perthus; Judith Rankin; Anke Rissmann; Florence Rouget; Bruno Schaub; David Tucker; Diana Wellesley; Katarzyna Wisniewska; Nataliia Zymak-Zakutnia; Ingeborg Barišić
Journal:  Am J Med Genet A       Date:  2019-07-11       Impact factor: 2.802

3.  An RNA aptamer restores defective bone growth in FGFR3-related skeletal dysplasia in mice.

Authors:  Takeshi Kimura; Michaela Bosakova; Yosuke Nonaka; Eva Hruba; Kie Yasuda; Satoshi Futakawa; Takuo Kubota; Bohumil Fafilek; Tomas Gregor; Sara P Abraham; Regina Gomolkova; Silvie Belaskova; Martin Pesl; Fabiana Csukasi; Ivan Duran; Masatoshi Fujiwara; Michaela Kavkova; Tomas Zikmund; Josef Kaiser; Marcela Buchtova; Deborah Krakow; Yoshikazu Nakamura; Keiichi Ozono; Pavel Krejci
Journal:  Sci Transl Med       Date:  2021-05-05       Impact factor: 17.956

4.  Sleep and upper airway obstruction in children with achondroplasia.

Authors:  M Zucconi; G Weber; V Castronovo; L Ferini-Strambi; F Russo; G Chiumello; S Smirne
Journal:  J Pediatr       Date:  1996-11       Impact factor: 4.406

5.  The population-based prevalence of achondroplasia and thanatophoric dysplasia in selected regions of the US.

Authors:  D K Waller; A Correa; Tuan M Vo; Y Wang; C Hobbs; P H Langlois; K Pearson; P A Romitti; G M Shaw; J T Hecht
Journal:  Am J Med Genet A       Date:  2008-09-15       Impact factor: 2.802

6.  Tyrosine kinase inhibitor NVP-BGJ398 functionally improves FGFR3-related dwarfism in mouse model.

Authors:  Davide Komla-Ebri; Emilie Dambroise; Ina Kramer; Catherine Benoist-Lasselin; Nabil Kaci; Cindy Le Gall; Ludovic Martin; Patricia Busca; Florent Barbault; Diana Graus-Porta; Arnold Munnich; Michaela Kneissel; Federico Di Rocco; Martin Biosse-Duplan; Laurence Legeai-Mallet
Journal:  J Clin Invest       Date:  2016-04-11       Impact factor: 14.808

7.  Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia.

Authors:  R Shiang; L M Thompson; Y Z Zhu; D M Church; T J Fielder; M Bocian; S T Winokur; J J Wasmuth
Journal:  Cell       Date:  1994-07-29       Impact factor: 41.582

8.  Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia.

Authors:  F Rousseau; J Bonaventure; L Legeai-Mallet; A Pelet; J M Rozet; P Maroteaux; M Le Merrer; A Munnich
Journal:  Nature       Date:  1994-09-15       Impact factor: 49.962

9.  In vitro and in vivo characterization of Recifercept, a soluble fibroblast growth factor receptor 3, as treatment for achondroplasia.

Authors:  Diogo Gonçalves; Guylène Rignol; Pierre Dellugat; Guido Hartmann; Stephanie Sarrazy Garcia; Jeffrey Stavenhagen; Luca Santarelli; Elvire Gouze; Christian Czech
Journal:  PLoS One       Date:  2020-12-28       Impact factor: 3.240

10.  Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study.

Authors:  Ravi Savarirayan; Louise Tofts; Melita Irving; William R Wilcox; Carlos A Bacino; Julie Hoover-Fong; Rosendo Ullot Font; Paul Harmatz; Frank Rutsch; Michael B Bober; Lynda E Polgreen; Ignacio Ginebreda; Klaus Mohnike; Joel Charrow; Daniel Hoernschemeyer; Keiichi Ozono; Yasemin Alanay; Paul Arundel; Yumiko Kotani; Natsuo Yasui; Klane K White; Howard M Saal; Antonio Leiva-Gea; Felipe Luna-González; Hiroshi Mochizuki; Donald Basel; Dania M Porco; Kala Jayaram; Elena Fisheleva; Alice Huntsman-Labed; Jonathan R S Day
Journal:  Genet Med       Date:  2021-08-02       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.